What CBN dose have studies used?
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| Sydney (Lavender 2026) | 30 mg or 300 mg, or matched placebo, once each in a crossover with a two-week washout, two hours before habitual lights out2 | Twenty adults with insomnia disorder2 | One night per dose |
| Bonn-Miller 2024 | Placebo, 20 mg CBN, or 20 mg CBN with 10, 20 or 100 mg CBD3 | Aged 18-55 with self-rated poor or very poor sleep3; 321 randomized, 293 consumed study product1 | Seven consecutive nights3 |
| Kolobaric 2024 | One softgel of 25, 50 or 100 mg CBN, or 4 mg melatonin or placebo, 1–2 hours before bedtime4 | 1020 adults1 | Four weeks1 |
| Saleska 2024 | 15 mg CBN with 15 mg CBD, alone or with 5 mg CBC or 5 mg melatonin, in capsules, compared with 15 mg CBD isolate5 | 1,793 adults with symptoms of sleep disturbance, across 6 products5 | 4 weeks5 |
| Hausenblas 2025 crossover pilot | Soft gel with 6 mg CBN, 3 mg THC, 10 mg CBD and 90 mg of a terpene blend, or placebo, an hour before sleep, with a two-week washout between conditions6 | 20 adults with subthreshold insomnia symptoms6 | 10 days per condition6 |
A review found that three key randomized trials gave oral CBN at 20 to 300 mg, from one night to four weeks, without identifying an optimal dose.1
Doses used in the sleep trials
The table is set at the top of the page
The Sydney trial gave a single oral liquid of CBN suspended in medium chain triglyceride oil.2 In that trial neither CBN dose significantly changed wake after sleep onset, the primary outcome.2 In the Bonn-Miller trial, compared with placebo, 20 mg CBN showed a nonsignificant but potentially meaningful effect on sleep quality (p = .082).3 In the Kolobaric trial, improvements in sleep quality did not differ significantly between any treatment group and the 4 mg melatonin group.4 In the Saleska trial, formulations with 15 mg CBD and 15 mg CBN did not differ significantly from 15 mg CBD isolate.5
Label and sold strengths
Searches of DailyMed, ClinicalTrials.gov and PubMed found no CBN label and no regulator-approved dose. The same searches found no list of the strengths CBN is sold in. The pilot authors say marketed cannabis sleep products typically contain 5 mg or less CBN.6 The Sydney authors say their 30 mg dose corresponds to typical community use of over-the-counter CBN products.2
Approval, legal status and absorption
A review says availability of CBN products does not establish an approved insomnia indication.1 The Sydney authors say CBN is Schedule 9 (prohibited substance) in Australia and can only be legally administered in a clinical trial with Government approval.2
The review says CBN is highly lipophilic and poorly water soluble, which may produce variable absorption.1 It adds that nominal milligrams alone are an incomplete exposure measure.1
Cycles, timing and oil volume
Searches of PubMed and the trial registry found no trial or label that gives a CBN cycle or stepping; each trial found used a fixed dose. The Sydney protocol authors say a single-dose design may lack ecological validity because repeated CBN dosing may be necessary.7
The Sydney trial gave each dose, 30 mg or 300 mg, as a 2 mL oral volume.2 The trial registry entry NCT05344170 describes a 2 mL oral dose of an oil with CBN at 15 mg/mL and a 2 mL oral dose of an oil with CBN at 150 mg/mL.82 No label found gives a syringe mark for CBN; the Sydney protocol says the study physician drew the fixed 2 mL volume into a prelabelled amber plastic syringe.7
Storage
Searches of PubMed and DailyMed found no CBN product label and no CBN-specific storage data for before or after opening. A review says stability requires product-specific evidence and that composition and storage can alter cannabinoid quality in carrier oils.1 A 2026 stability study of CBD- and THC-rich products, not CBN products, found CBD-only products stable long term at room temperature, and THC-rich products most stable as ethanolic solutions stored in the freezer at -20°C.9
Frequently asked questions
What side effects were reported at these doses?
The Kolobaric authors say the study supports safety of CBN with mild to moderate side effects reported over six weeks, a span that includes a baseline week and one week after the four weeks of product use.4 In the Saleska trial, across all six products, of which only some contained CBN, 12% of participants reported a side effect and none were severe.5 The Sydney trial paper reports 247 mild-to-moderate adverse events across its arms.2 The Hausenblas pilot authors say no adverse events were reported.6
Are other CBN trials registered?
Registry entry NCT07769164, completed with an actual enrolment of 332, lists gummy arms with 20 mg CBN, 10 mg THC and 5 mg CBG, and with 5 mg CBN, 10 mg THC, 5 mg CBG and 20 mg CBD, against placebo.10
References
- Nutrients. Cannabinol for Sleep and Insomnia: A Critical Narrative Review and an Olive-Derived Polyphenol Combination Hypothesis. 2026. pmc.ncbi.nlm.nih.gov
- Journal article. Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo‐Controlled Crossover Trial. pmc.ncbi.nlm.nih.gov
- Journal article (PubMed). A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. 2024. pubmed.ncbi.nlm.nih.gov
- Pharmaceuticals (Basel). A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN™ for Improving Sleep. 2024. pmc.ncbi.nlm.nih.gov
- Journal article (PubMed). The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. 2024. pubmed.ncbi.nlm.nih.gov
- Journal article. Effectiveness of a Cannabinoids Supplement on Sleep and Mood in Adults With Subthreshold Insomnia: A Randomized Double‐Blind Placebo‐Controlled Crossover Pilot Trial. 2025. pmc.ncbi.nlm.nih.gov
- BMJ Open. Cannabinol (CBN; 30 and 300 mg) effects on sleep and next-day function in insomnia disorder (‘CUPID’ study): protocol for a randomised, double-blind, placebo-controlled, cross-over, three-arm, proof-of-concept trial. 2023. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT05344170: Cannabinol Use in Patients With Insomnia Disorder. 2023. clinicaltrials.gov
- Cannabis Cannabinoid Res. Stability of Cannabinoids in Cannabis: Plant Material, Extracts, Oil Formulations, and Isolates (CBD and Δ9-THC) Under Different Storage Conditions. 2026. pubmed.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT07769164: A Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Effects of Various Cannabinoids on Sleep Quality. 2024. clinicaltrials.gov